Shes a book author and freelance writer specializing in diabetes care and education
Patients pay a flat monthly rate for their chosen medication tierwhether that is the Microdose Protocol at $129/month, compounded semaglutide at $189/month, or compounded tirzepatide at $289/month
This is not a market full of patients starting from scratch
How the fast-food industry is responding in the booming era of GLP-1s Fast food chains are figuring out how to respond to the drastic drop in calories being consumed by Americans, Rhian Lubin reports Rhian Lubin reports Bookmark CommentsGo to comments With the use of GLP-1 medications skyrocketing in the United States, youd be forgiven for thinking the new weight loss era could sound a death knell for Americas fast food industry
That benefit far outweighs the small risk associated with surgery, which has a complication rate lower than hip replacement surgery
WeightWatchers own data shows people combining a GLP-1 with its program lose substantially more than with the app alone, which is the same story playing out across the whole industry: the medication is the main driver, and the behavioral program supports it